Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target

Cancer Chemotherapy and Pharmacology

Volumn 34, Issue 6, 1994, Pages 459-464

  Scambia, G ^a   Ranelletti, F O ^a   Panici, P Benedetti ^a   De Vincenzo, R ^a   Bonanno, G ^a   Ferrandina, G ^a   Piantelli, M ^a   Bussa, S ^a   Rumi, C ^a   Cianfriglia, M ^b   Mancuso, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b I S S Rome ^*  (Italy)

Author keywords

Adriamycin; Human breast cancer cells; Multidrug resistance; Quercetin

Indexed keywords

3',4',7 TRIMETHOXYQUERCETIN; DOXORUBICIN; GLYCOPROTEIN P; QUERCETIN; RUTOSIDE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; FLOW CYTOMETRY; HUMAN; P-GLYCOPROTEIN; QUERCETIN; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0027981909     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00685655     Document Type: Article

References (42)

1. Mechanisms of multidrug resistance in cancer treatment
2. P-glycoprotein epitope mapping. Identification of a linear human-specific epitope in the fourth loop of the P-glycoprotein extracellular domain by MM4.17 murine monoclonal antibody to human multidrug resistance cells
3. Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line
4. Adverse interaction between cytotoxic drugs and hormonal agents in human breast cancer cells (Let)
5. Pharmacological and suprapharmacological concentrations of both 17β estradiol (E2) and tamoxifen (TAM) reduce the membrane fluidity of MCF-7 and MDA-MB-436 human breast cancer cells
6. Multidrug resistance activity in human lymphocytes
7. Multifactorial resistance to Adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of Adriamycin-sensitive and-resistant P388 leukemia
8. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin sensitive and resistant P388 leukemia cell lines
9. Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance
10. Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors
11. Isolation of amplified and over-expressed DNA sequences from Adriamycinresistant human breast cancer cells
12. Modulation of induced resistance to Adriamycin in two human breast cancer cell lines with tamoxifen or perphexiline maleate
13. Szent-Gyorgyi and the bioflavonoids: new results and perspectives of pharmacological research into benzo-pirene derivates
14. Resistance to multiple chemotherapeutic agents in human cancer cells
15. Disposition of quercetin in man after single oral and intravenous doses
16. Enhancement of the antiproliferative activity of cis-diaminedichloroplatinum by quercetin
17. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
18. Quercetin, a bioflavonoid, inhibits the increase of human multidrug resistance gene (MDR1) expression caused by arsenite
19. Role of the glutathione redox cycle in acquired and de novo multidrug resistance
20. Type II oestrogen binding sites in acute lymphoid and non-lymphoid leukaemias: growth inhibitory effect of oestrogen and flavonoids
21. Biochemical modulation of anthracycline resistance (MDR) in acute leukemia with cyclosporin-A (CsA)
22. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123
23. Flavonoid inhibition of human basophil histamine release stimulated by various agents
24. The role of DNA polymerase α and β in DNA repair synthesis induced in hamster and human cells by different DNA damaging agents
25. Clinical modulation of doxorubicin resistance by the calmodulin inhibitor, trifluoperazine: a phase I/II trial
26. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil
27. Use of fluorescent dyes as molecular probes for the study of multidrug resistance
28. Verapamil and adriamycin in the treatment of drug resistant ovarian cancer patients
29. Plasma membrane lipid structural order in doxorubicin sensitive and resistant P388 cells
30. Growth-inhibitory effect of quercetin and presence of type II oestrogen binding sites in human colorectal cell lines and primary colorectal tumours
31. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as chemosensitizer
32. Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance
33. Inhibitory effect of quercetin of OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells
34. Type II estrogen binding sites in a lymphoblastoid cell line and growth inhibitory effect of estrogen, antiestrogen and bioflavonoids
35. Synergistic antiproliferative activity of quercetin and cis-diamminedichloroplatinum on ovarian cancer cell growth
36. Quercetin inhibits the growth of a multidrugresistant estrogen receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites
37. Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic antiproliferative activity with cis-diamminedichloroplatinum(II)
38. Anthracyclines
39. The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth
40. Multi-drug resistance
41. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo
42. Proof without prejudice: use of the Kolmogorov-Smirnov test for analysis of histograms from flow systems and other sources